Additionally, the 36-month beta value for FULC is 2.27. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for FULC is 57.79M and currently, short sellers hold a 6.21% ratio of that float. The average trading volume of FULC on June 26, 2024 was 552.93K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
FULC) stock’s latest price update
Fulcrum Therapeutics Inc (NASDAQ: FULC)’s stock price has decreased by -4.01 compared to its previous closing price of 5.98. However, the company has seen a -11.56% decrease in its stock price over the last five trading sessions. zacks.com reported 2024-05-15 that The consensus price target hints at a 69.2% upside potential for Fulcrum Therapeutics (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
FULC’s Market Performance
Fulcrum Therapeutics Inc (FULC) has experienced a -11.56% fall in stock performance for the past week, with a -20.39% drop in the past month, and a -37.13% drop in the past quarter. The volatility ratio for the week is 6.84%, and the volatility levels for the past 30 days are at 6.19% for FULC. The simple moving average for the past 20 days is -23.48% for FULC’s stock, with a -15.33% simple moving average for the past 200 days.
Analysts’ Opinion of FULC
Many brokerage firms have already submitted their reports for FULC stocks, with Cantor Fitzgerald repeating the rating for FULC by listing it as a “Overweight.” The predicted price for FULC in the upcoming period, according to Cantor Fitzgerald is $23 based on the research report published on May 20, 2024 of the current year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see FULC reach a price target of $14. The rating they have provided for FULC stocks is “Outperform” according to the report published on March 13th, 2024.
Goldman gave a rating of “Neutral” to FULC, setting the target price at $5 in the report published on September 25th of the previous year.
FULC Trading at -23.14% from the 50-Day Moving Average
After a stumble in the market that brought FULC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.10% of loss for the given period.
Volatility was left at 6.19%, however, over the last 30 days, the volatility rate increased by 6.84%, as shares sank -26.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.42% lower at present.
During the last 5 trading sessions, FULC fell by -12.02%, which changed the moving average for the period of 200-days by +9.81% in comparison to the 20-day moving average, which settled at $7.40. In addition, Fulcrum Therapeutics Inc saw -14.96% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FULC starting from Tourangeau Greg, who sale 236 shares at the price of $7.76 back on May 07 ’24. After this action, Tourangeau Greg now owns 11,571 shares of Fulcrum Therapeutics Inc, valued at $1,831 using the latest closing price.
Tourangeau Greg, the Vice President, Finance of Fulcrum Therapeutics Inc, sale 4,884 shares at $11.72 during a trade that took place back on Mar 08 ’24, which means that Tourangeau Greg is holding 11,807 shares at $57,219 based on the most recent closing price.
Stock Fundamentals for FULC
Current profitability levels for the company are sitting at:
- -44.84 for the present operating margin
- 0.17 for the gross margin
The net margin for Fulcrum Therapeutics Inc stands at -39.61. The total capital return value is set at -0.51. Equity return is now at value -39.00, with -35.91 for asset returns.
Based on Fulcrum Therapeutics Inc (FULC), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -9.09. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -35.61.
Currently, EBITDA for the company is -108.49 million with net debt to EBITDA at 0.27. When we switch over and look at the enterprise to sales, we see a ratio of 130.51. The receivables turnover for the company is 2.32for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 20.38.
Conclusion
In conclusion, Fulcrum Therapeutics Inc (FULC) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
